Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Why Moderna Shares Are Rising Again Today

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 8.5% to $214.34 on continued upward momentum after the company and Merck announced mRNA-4157/V940 in combination with KEYTRUDA, met the primary efficacy endpoint in the Phase 2b KEYNOTE-942 trial.
byHenry Khederian
December 14, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Moderna Inc (NASDAQ:MRNA) shares are trading higher by 8.5% to $214.34 on continued upward momentum after the company and Merck announced mRNA-4157/V940 in combination with KEYTRUDA, met the primary efficacy endpoint in the Phase 2b KEYNOTE-942 trial.

The results showed that mRNA cancer vaccine + Keytruda demonstrated a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS) versus Keytruda alone for the adjuvant treatment of stage III/IV melanoma following complete resection…Read More

See Also: Moderna Soars On Cancer Vaccine News: Here’s What To Watch Going Forward

According to data from Benzinga Pro, MRNA has a 52-week high of $321.30 and a 52-week low of $115.03.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Grand Theft Auto Maker Take-Two Reports Soft Q3 Results, Lowers 2024 Forecast

By Erica Kollmann
February 8, 5:43 PM
Take-Two Interactive Software reported quarterly total net bookings of $1.34 billion which is down 3% year-over-year. Take-Two said net bookings from recurrent consumer spending decreased by 7% and accounted for 75% of total net bookings. The company reported GAAP net revenue of $1.37 billion, also down by 3%, and a GAAP loss per share of 54 cents. Take-Two also revised its 2024 net bookings forecast to between $5.25 billion and $5.3 billion.

NXT